Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
141
resultados
Última actualización
06/05/2026 [08:25:00]
Resultados 125 a 141 de 141
Resumen de: AU2026201302A1
The invention provides antibodies or binding fragments thereof directed against citrulline containing epitopes. The antibodies or binding fragments thereof of the invention can be 5 used in therapy, for example in the treatment or prevention ofNeutrophil Extracellular Trap (NET)-associated pathologies. The antibodies or binding fragments thereof of the invention can be used in the treatment or prevention of NET-associated pathologies such as systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune 10 hepatitis, juvenile idiopathic arthritis, Sjogren' s disease, Anti-phospholipid Syndrome, Bechet's disease, spondylitis, spondyloarthropathy, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbated asthma, allergic asthma, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, dry eye disease, uveitis, nongranulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, 15 bronchitis, or other NET-associated pathologies such as wound healing in diabetes, cancer, cancer metastasis, and transplant organ health in vivo or ex vivo. The invention also provides pharmaceutical compositions and methods for treating or preventing NET associated pathologies such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune
Resumen de: WO2026052795A1
The present invention provides a formulation of metformin and glibenclamide for the prevention and/or treatment of neurodegenerative diseases, preferably chosen among Parkinson's disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal dementia, Lewy body dementia, Huntington's disease and Alzheimer's disease.
Resumen de: US20260071275A1
The present disclosure provides compositions and methods using C9ORF72-mediated genes and expression products thereof for diagnosis, treatment and prevention of amyotrophic lateral sclerosis, frontotemporal dementia, or both, in carriers of a C9ORF72 hexanucleotide expansion. The present invention also relates to a method of identifying therapeutic agents to treat and diagnose amyotrophic lateral sclerosis, frontotemporal dementia, or both, in carriers of a C9ORF72 hexanucleotide expansion based on C9ORF72-mediated genes.
Resumen de: US20260072043A1
The present disclosure provides methods for diagnosing or determining susceptibility to Alzheimer's Disease a subject by obtaining a biological sample from the subject; detecting one or more biomarkers in the biological sample selected from the group consisting of: inflammation biomarkers, oxidative stress biomarkers, insulin resistance biomarkers, and autophagy biomarkers; and diagnosing the subject with Alzheimer's Disease where one or more of the biomarkers is detected in the biological sample. Also provided are methods of treating a subject with Alzheimer's Disease comprising administering to the subject an effective amount of one or more agents for the treatment of inflammation, oxidative stress, insulin resistance, and/or autophagy.
Resumen de: WO2026052700A1
Provided herein is an anti-CD2 antibody or antigen binding fragment thereof for treating and/or preventing ALS in a subject in need thereof.
Resumen de: AU2024334698A1
Provided is an antibody that binds to β-amyloid (Aβ), or an antigen-binding fragment thereof. Further provided are a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a cell comprising the antibody or the antigen-binding fragment or nucleic acid thereof, a pharmaceutical composition, a kit, and the use of the antibody or the antigen-binding fragment thereof in the preparation of a drug used for treating or preventing a disease caused by abnormal accumulation or deposition of Aβ in subjects.
Resumen de: AU2024335242A1
This disclosure relates to methods and compositions for the treatment of Parkinson's disease, a neurodegenerative disorder characterized by a loss of dopaminergic neurons. In particular, this disclosure provides formulations of dopaminergic cells demonstrated to possess a therapeutic impact on both motor and non-motor symptoms of the disease.
Resumen de: WO2024229414A2
Neurodegenerative diseases are treated by the co-administration to a subject of an effective amount of a stilbene, a flavonol, and a TLR4/MD2 receptor antagonist. A preferred stilbene is resveratrol, a preferred flavonol is quercetin, and a preferred TLR4/MD2 receptor antagonist is curcumin.
Resumen de: US2024368188A1
0000 6,7-Dihydrothiazolo5,4-cpyridines substituted in the 5-position with heterocyclic rings are positive allosteric modulators of the muscarinic acetylcholine receptor Ma (mAChR MA) and may have use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.
Resumen de: GB2700773A
A compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein Ring A is selected from: R1 is: halo, -CN, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -O-C1-C6 alkyl or -SO2-C1-C6 alkyl; R2 is: H, halo, or -CN; R3, R5, and R6 are each independently: H, halo, or -O-C1-C6 alkyl; R4 is independently: halo, -CN, C1-C6 alkyl, -O-C1-C6 alkyl, C3-C6 cycloalkyl, -O-C3-C6 cycloalkyl, or -O-C1-C6 alkyl-C3-C6 cycloalkyl; wherein said C1-C6 alkyl, -O-C1-C6 alkyl, C3-C6 cycloalkyl, -O-C3-C6 cycloalkyl, and -O-C1-C6 alkyl-C3-C6 cycloalkyl, are optionally substituted with from 1 to 6 groups each independently: deuterium, -CN, halo, -O-C1-C3 alkyl, or -O-C1-C3 haloalkyl; R7 is halo, or -O-C1-C6 alkyl; X1 is CR8; and R8 is H, halo, C1-C6 alkyl, C1-C6 haloalkyl, -O-C1-C6 alkyl, or -O-C1-C6 haloalkyl. The compounds are GPR17 modulators. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases and conditions associated with GPR17, including multiple sclerosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). Figure formula (I)
Resumen de: EP4706655A1
The purpose of the present invention is to provide a medicinal agent that exhibits the effect of inhibiting aggregation of a causative protein of an HRE-related neurodegenerative disease such as ALS. According to the present invention, rifampicin or a rifampicin compound selected from the group consisting of rifampicin, a derivative thereof, and a salt of rifampicin or the derivative and/or resveratrol or a resveratrol compound selected from the group consisting of resveratrol and a derivative thereof is an active ingredient of a preventive or therapeutic agent for a neurodegenerative disease caused by TDP-43 accumulation, or an active ingredient of a preventive or therapeutic agent for ALS.
Resumen de: EP4707410A2
0001 Disclosed herein are methods and compositions that can be used to improve motor deficits and neuroinflammation in subjects in need, for example subjects suffering from neurodegenerative disorders (e.g., Parkinson's disease). Also disclosed are methods and compositions that can be used to diagnose neurodegenerative disorders, such as Parkinson's disease.
Resumen de: EP4706644A1
0001 The present invention relates to: reconstituted high-density lipoprotein nanoparticles comprising cholesterol; and a composition for preventing or treating Alzheimer's disease and cancer, the composition comprising the nanoparticles. Specifically, the reconstituted high-density lipoprotein nanoparticles comprising cholesterol according to the present invention have an excellent cell influx rate and promote cholesterol efflux from cells, thus having a cancer cell killing effect, and can therefore be used for preventing or treating cancer.
Resumen de: KR20260032816A
본 발명은 알츠하이머병 예방 또는 치료용 약학 조성물에 관한 것으로서, 보다 상세하게는, miR-4536-3p 억제제를 포함함으로써 신경세포의 세포사멸을 억제하여 알츠하이머병을 예방 또는 치료할 수 있는 신규한 알츠하이머병 예방 또는 치료용 약학 조성물에 관한 것이다.
Resumen de: KR20260032814A
본 발명은 알츠하이머병 예방 또는 치료용 약학 조성물에 관한 것으로서, 보다 상세하게는, miR-4284 억제제를 포함함으로써 신경세포의 세포사멸을 억제하여 알츠하이머병을 예방 또는 치료할 수 있는 신규한 알츠하이머병 예방 또는 치료용 약학 조성물에 관한 것이다.
Nº publicación: KR20260032813A 10/03/2026
Solicitante:
전남대학교산학협력단주식회사스템셀바이오
Resumen de: KR20260032813A
본 발명은 알츠하이머병 예방 또는 치료용 약학 조성물에 관한 것으로서, 보다 상세하게는, miR-937-3p 억제제를 포함함으로써 신경세포의 세포사멸을 억제하여 알츠하이머병을 예방 또는 치료할 수 있는 신규한 알츠하이머병 예방 또는 치료용 약학 조성물에 관한 것이다.
BOPI
Sede Electrónica
